CDKN1B


Also found in: Wikipedia.

CDKN1B

A gene on chromosome 12p13.1-p12 that encodes a cyclin-dependent kinase inhibitor, which binds to and prevents activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, thus controlling cell cycle progression at G1. Degradation of cyclin-dependent kinase inhibitor 1B is triggered by its CDK-dependent phosphorylation and subsequent ubiquitination by SCF complexes, and is a necessary step for cell transition from quiescence to the proliferative state.
Mentioned in ?
References in periodicals archive ?
B binding protein Transforming growth factor, beta 2 TCFBR2 Transforming growth factor, beta receptor II TCF/Smad pathway SMAD1 SMAD family member 1 SMAD6 SMAD family member 6 S0X4 SRY (sex determining region Y)-box 4 SP1 Spl transcription factor CTNNB1 CREB binding protein Ras/MAPK(non-Smad) RHOA Ras homolog gene family, pathway member A RH08 Ras homolog gene family, member B MAP3K7 Mitogen-activated protein kinase kinase kinase 7 MAPK14 Mitogen-activated protein kinase 14 Downstream effector BCL2L1 BCL2-like 1 CDC6 Cell division cycle 6 homolog CDKN1B Cyclin-dependent kinase inhibitor 1B CEBPB CCAAT/enhancer binding protein (C/EBP), beta FN1 Fibronectin 1 CADD45B Growth arrest and DNA-damage-inducible.
Activated Akt also promotes cell cycle transition through the regulation of CDKN1B [encoded by cyclin-dependent kinase inhibitor 1B (CDKN1B)], GSK3B [encoded by glycogen synthase kinase 3 beta (GSK3B)], and mTOR [encoded by mammalian target of rapamycin (MTOR)] signaling.
The most studied regulation in this context is the regulation of CDKN1B by miR-221/-222 (12, 36-38).
The wide array of molecular-based PCa markers includes proliferation index (Ki-67), microvessel density, nuclear morphometry, tumor suppressor genes (eg, TP53, CDKN1A, CDKN1B, NKX3-1, PTEN, and the retinoblastoma gene Rb), oncogenes (eg, BCL2, MYC, EZH2, and ERBB2 [formerly HER2/neu]), adhesion molecules (eg, CD44 and E-cadherin), the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, (30,31) apoptosis regulators (eg, survivin and transforming growth factor p1), androgen receptor status, neuroendocrine differentiation markers, and prostate tissue lineage-specific markers (PSA, prostate-specific acid phosphatase, and prostate-specific membrane antigen).